FDA panel debates merits of next-generation opioid formulations.
Lavine
Greg
G
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations; D017277:Drug Approval; D006801:Humans; D009020:Morphine / Q000008:administration & dosage / Q000737:chemistry; D009271:Naltrexone / Q000008:administration & dosage / Q000737:chemistry; D010098:Oxycodone / Q000008:administration & dosage / Q000737:chemistry; D014481:United States; D014486:United States Food and Drug Administration
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D009271:Naltrexone; D009020:Morphine; D010098:Oxycodone